JP2019502095A5 - - Google Patents

Download PDF

Info

Publication number
JP2019502095A5
JP2019502095A5 JP2018519871A JP2018519871A JP2019502095A5 JP 2019502095 A5 JP2019502095 A5 JP 2019502095A5 JP 2018519871 A JP2018519871 A JP 2018519871A JP 2018519871 A JP2018519871 A JP 2018519871A JP 2019502095 A5 JP2019502095 A5 JP 2019502095A5
Authority
JP
Japan
Prior art keywords
hmwk
subject
level
disease
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018519871A
Other languages
English (en)
Japanese (ja)
Other versions
JP6903648B2 (ja
JP2019502095A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/057640 external-priority patent/WO2017070170A1/en
Publication of JP2019502095A publication Critical patent/JP2019502095A/ja
Publication of JP2019502095A5 publication Critical patent/JP2019502095A5/ja
Priority to JP2021104359A priority Critical patent/JP7238027B2/ja
Application granted granted Critical
Publication of JP6903648B2 publication Critical patent/JP6903648B2/ja
Priority to JP2023031415A priority patent/JP7640599B2/ja
Priority to JP2025025949A priority patent/JP2025081553A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018519871A 2015-10-19 2016-10-19 切断高分子量キニノーゲンを検出するイムノアッセイ Active JP6903648B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021104359A JP7238027B2 (ja) 2015-10-19 2021-06-23 切断高分子量キニノーゲンを検出するイムノアッセイ
JP2023031415A JP7640599B2 (ja) 2015-10-19 2023-03-01 切断高分子量キニノーゲンを検出するイムノアッセイ
JP2025025949A JP2025081553A (ja) 2015-10-19 2025-02-20 切断高分子量キニノーゲンを検出するイムノアッセイ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562243505P 2015-10-19 2015-10-19
US62/243,505 2015-10-19
US201662335311P 2016-05-12 2016-05-12
US62/335,311 2016-05-12
PCT/US2016/057640 WO2017070170A1 (en) 2015-10-19 2016-10-19 Immunoassay to detect cleaved high molecular weight kininogen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021104359A Division JP7238027B2 (ja) 2015-10-19 2021-06-23 切断高分子量キニノーゲンを検出するイムノアッセイ

Publications (3)

Publication Number Publication Date
JP2019502095A JP2019502095A (ja) 2019-01-24
JP2019502095A5 true JP2019502095A5 (https=) 2019-11-28
JP6903648B2 JP6903648B2 (ja) 2021-07-14

Family

ID=57233867

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018519871A Active JP6903648B2 (ja) 2015-10-19 2016-10-19 切断高分子量キニノーゲンを検出するイムノアッセイ
JP2021104359A Active JP7238027B2 (ja) 2015-10-19 2021-06-23 切断高分子量キニノーゲンを検出するイムノアッセイ
JP2023031415A Active JP7640599B2 (ja) 2015-10-19 2023-03-01 切断高分子量キニノーゲンを検出するイムノアッセイ
JP2025025949A Pending JP2025081553A (ja) 2015-10-19 2025-02-20 切断高分子量キニノーゲンを検出するイムノアッセイ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021104359A Active JP7238027B2 (ja) 2015-10-19 2021-06-23 切断高分子量キニノーゲンを検出するイムノアッセイ
JP2023031415A Active JP7640599B2 (ja) 2015-10-19 2023-03-01 切断高分子量キニノーゲンを検出するイムノアッセイ
JP2025025949A Pending JP2025081553A (ja) 2015-10-19 2025-02-20 切断高分子量キニノーゲンを検出するイムノアッセイ

Country Status (17)

Country Link
US (2) US10914747B2 (https=)
EP (3) EP4354146B1 (https=)
JP (4) JP6903648B2 (https=)
KR (2) KR20240133761A (https=)
CN (2) CN108291917B (https=)
AU (2) AU2016340826C1 (https=)
BR (1) BR112018007842A2 (https=)
CA (1) CA3002747A1 (https=)
CO (1) CO2018004289A2 (https=)
DK (1) DK3365685T3 (https=)
EA (1) EA201891002A1 (https=)
ES (2) ES2857552T3 (https=)
IL (3) IL326475A (https=)
MX (2) MX2018004763A (https=)
PL (2) PL3365685T3 (https=)
PT (1) PT3365685T (https=)
WO (1) WO2017070170A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014113712A1 (en) 2013-01-20 2014-07-24 Dyax Corp. Evaluation and treatment of bradykinin-mediated disorders
JP6757252B2 (ja) 2013-10-21 2020-09-16 ダイアックス コーポレーション 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
CA2927695C (en) 2013-10-21 2022-03-01 Dyax Corp. Diagnosis and treatment of autoimmune diseases
KR20240133761A (ko) 2015-10-19 2024-09-04 다케다 파머수티컬 컴패니 리미티드 절단된 고분자량 키니노겐의 검출을 위한 면역검정법
WO2019075097A1 (en) * 2017-10-11 2019-04-18 Board Of Regents, The University Of Texas System PD-L1 HUMAN ANTIBODIES AND METHODS OF USE
CN119101158A (zh) 2018-03-23 2024-12-10 得克萨斯州大学系统董事会 人pd-l2抗体及其使用方法
EP3768726B1 (en) 2018-03-23 2024-10-30 Board of Regents, The University of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
WO2019182867A1 (en) 2018-03-23 2019-09-26 Board Of Regents, The University Of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
CN112424357B (zh) * 2018-06-26 2024-12-24 协和麒麟株式会社 与硫酸软骨素蛋白聚糖5结合的抗体

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1312564C (en) 1985-07-12 1993-01-12 Robert W. Colman Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same
US4908431A (en) 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US5047323A (en) * 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
KR960009766B1 (ko) 1986-09-10 1996-07-24 니혼 소오끼 세이야꾸 가부시기가이샤 생리 활성물질 측정법
US4882272A (en) 1986-10-01 1989-11-21 Temple University - Of The Commonwealth System Of Higher Education High molecular weight kininogen assay
US5025796A (en) 1988-12-01 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU2548992A (en) 1991-08-13 1993-03-16 Temple University - Of The Commonwealth System Of Higher Education Modulation of blood pressure and inhibition of platelet activation with kininogen fragment
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
PT739355E (pt) 1994-01-11 2005-01-31 Dyax Corp Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
JPH1084995A (ja) * 1996-09-12 1998-04-07 Nippon Zoki Pharmaceut Co Ltd 血液凝固第ｘｉｉ因子活性化法
US5789261A (en) * 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
US6242210B1 (en) 1997-05-20 2001-06-05 Actinova Limited Treatment of bacterial infections
JP4346798B2 (ja) * 1999-08-19 2009-10-21 協和メデックス株式会社 Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。
US6994852B1 (en) 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US7678541B2 (en) 2000-11-21 2010-03-16 Hologic, Inc. Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction
JP2002221519A (ja) * 2001-01-29 2002-08-09 Sysmex Corp 抗凝固剤およびそれを用いた抗凝固剤処理方法
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
US6913900B2 (en) * 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
WO2004005934A2 (en) 2002-07-04 2004-01-15 Oxford Glycosciences (Uk) Ltd Toxicity markers
US20070003552A1 (en) 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
SI1981519T1 (en) 2005-12-29 2018-05-31 Dyax Corp. INHIBITION PROTEAZE
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
JP5322935B2 (ja) 2006-07-31 2013-10-23 アクティベサイト ファーマシューティカルズ インコーポレイティッド 血漿カリクレインの阻害薬
EP2089712A4 (en) 2006-11-22 2010-09-22 Life Technologies Corp BIOMARKERS OF AUTOIMMUNE DISEASES
CA2696208A1 (en) 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
EP2216651A4 (en) 2007-10-18 2010-12-01 Miyazaki Prefectural Ind Suppo BIOMARKERS FOR THE DIAGNOSIS OF LIVER DISEASE
AU2008315938B2 (en) 2007-10-22 2014-11-27 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
AU2009269257A1 (en) 2008-07-07 2010-01-14 Nippon Zoki Pharmaceutical Co., Ltd. Method for detection of fibromyalgia
US20110212104A1 (en) 2008-11-03 2011-09-01 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
EP2369930A4 (en) 2008-12-02 2012-10-03 Joslin Diabetes Ct METHOD OF REDUCING BLOOD PRESSURE USING PLASMATIC KALLICREIN INHIBITORS
CA2744235A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
FR2942233B1 (fr) * 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
KR101077275B1 (ko) 2009-05-07 2011-10-27 한국기초과학지원연구원 당단백질의 당쇄화를 이용한 암 진단 방법
JP5299179B2 (ja) 2009-09-02 2013-09-25 株式会社リコー 画像形成装置
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US9206123B2 (en) 2009-12-18 2015-12-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
EP2512466A4 (en) 2009-12-18 2013-07-03 Activesite Pharmaceuticals Inc PRODRUGS OF INHIBITORS OF PLASMATIC KALLICREIN
EP3459564B1 (en) 2010-01-06 2021-10-27 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
WO2012009447A2 (en) 2010-07-13 2012-01-19 University Of Rochester THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF
US10299714B2 (en) * 2010-12-02 2019-05-28 Becton, Dickinson And Company Blood collection devices containing blood stabilization agent including variegin or analog thereof and/or a polysulfated disaccharide
CA2823776A1 (en) 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
US9315811B2 (en) 2011-06-10 2016-04-19 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (KLKB1) expression
WO2012170947A2 (en) 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
FR2983215B1 (fr) 2011-11-28 2013-12-20 Univ Grenoble 1 Dosage de la capacite de controle de c1inh
WO2014113712A1 (en) * 2013-01-20 2014-07-24 Dyax Corp. Evaluation and treatment of bradykinin-mediated disorders
JP2016505159A (ja) * 2013-02-01 2016-02-18 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 接触経路抑制添加剤を含む血液採集装置
CA2927695C (en) 2013-10-21 2022-03-01 Dyax Corp. Diagnosis and treatment of autoimmune diseases
JP6757252B2 (ja) 2013-10-21 2020-09-16 ダイアックス コーポレーション 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
AU2015209481C1 (en) * 2014-01-21 2020-10-29 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
KR20240133761A (ko) * 2015-10-19 2024-09-04 다케다 파머수티컬 컴패니 리미티드 절단된 고분자량 키니노겐의 검출을 위한 면역검정법
EP3390439B1 (en) 2015-12-15 2025-03-12 Takeda Pharmaceutical Company Limited Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk
WO2021094587A1 (en) 2019-11-13 2021-05-20 eV-Technologies Spin-wave based magnetic and/or electro-magnetic field sensing device for dc, rf and millimeter-wave applications
EP4096687A4 (en) 2020-01-28 2024-02-28 Orgenesis Inc. Process and system for acellular therapy

Similar Documents

Publication Publication Date Title
JP2019502095A5 (https=)
US9134326B2 (en) Biomarkers for liver fibrosis
US7803553B2 (en) Methods of use of antibodies which recognize a protease cleavage site of an LAP fragment of TGF-β
LaFauci et al. Fragile X screening by quantification of FMRP in dried blood spots by a Luminex immunoassay
IL312916A (en) Immunoassay to detect cleaved high molecular weight kininogen
JPWO2003085399A1 (ja) 白血病、前白血病または非白血病性悪性血液疾患の判定方法及び診断薬
JP5766606B2 (ja) 輸血関連急性肺障害（ｔｒａｌｉ）に関するスクリーニング方法
JP2019532633A5 (https=)
Burgener et al. A systems biology examination of the human female genital tract shows compartmentalization of immune factor expression
US10379108B2 (en) Distinction of infectious virus based on molecular biomarker and neutralization of virus causing food poisoning
Chang et al. The diagnosis and classification of autoimmune coagulopathy: an updated review
US20200271651A1 (en) Methods, compositions, and kits for detection of aspergillosis
Pierangeli et al. New targeted therapies for treatment of thrombosis in antiphospholipid syndrome
US20180284131A1 (en) Diagnostic assays for supar-β3 integrin driven kidney diseases
JP5524241B2 (ja) 腎症と関連するバイオマーカー
Wiederin et al. Plasma proteomic analysis of simian immunodeficiency virus infection of rhesus macaques
AU2016273230A1 (en) Biomarkers for a combination therapy comprising lenvatinib and everolimus
EP3861347A1 (en) Biomarkers for a combination therapy comprising lenvatinib and everolimus
US20220144939A1 (en) Antibody therapies and methods for treating coronavirus infection
JP2019529906A5 (https=)
US10295550B2 (en) Compositions and methods for use in diagnosis of alzheimer's disease
Perico et al. SARS-CoV-2 spike protein 1 activates microvascular endothelial cells and complement system leading to thrombus formation
EP3177312B1 (en) Method and kit for detecting bacterial infection
JP7783637B2 (ja) ネフローゼ症候群の診断を補助するためのマーカー及びその使用
JP6407990B2 (ja) アウグリン免疫学的検定